Logo image of TCRX

TSCAN THERAPEUTICS INC (TCRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TCRX - US89854M1018 - Common Stock

1.02 USD
+0.02 (+2%)
Last: 1/2/2026, 8:00:01 PM
1.03 USD
+0.01 (+0.98%)
After Hours: 1/2/2026, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, TCRX scores 2 out of 10 in our fundamental rating. TCRX was compared to 530 industry peers in the Biotechnology industry. While TCRX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, TCRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TCRX had negative earnings in the past year.
TCRX had a negative operating cash flow in the past year.
TCRX had negative earnings in each of the past 5 years.
TCRX had a negative operating cash flow in each of the past 5 years.
TCRX Yearly Net Income VS EBIT VS OCF VS FCFTCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

TCRX has a Return On Assets (-54.38%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -99.01%, TCRX is in line with its industry, outperforming 46.23% of the companies in the same industry.
Industry RankSector Rank
ROA -54.38%
ROE -99.01%
ROIC N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
TCRX Yearly ROA, ROE, ROICTCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

TCRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRX Yearly Profit, Operating, Gross MarginsTCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TCRX has more shares outstanding than it did 1 year ago.
TCRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TCRX has been reduced compared to a year ago.
TCRX Yearly Shares OutstandingTCRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TCRX Yearly Total Debt VS Total AssetsTCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TCRX has an Altman-Z score of -3.39. This is a bad value and indicates that TCRX is not financially healthy and even has some risk of bankruptcy.
TCRX has a Altman-Z score (-3.39) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.23 indicates that TCRX is not too dependend on debt financing.
The Debt to Equity ratio of TCRX (0.23) is worse than 65.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -3.39
ROIC/WACCN/A
WACC9.41%
TCRX Yearly LT Debt VS Equity VS FCFTCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.44 indicates that TCRX has no problem at all paying its short term obligations.
TCRX has a better Current ratio (6.44) than 66.23% of its industry peers.
A Quick Ratio of 6.44 indicates that TCRX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.44, TCRX is doing good in the industry, outperforming 66.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.44
Quick Ratio 6.44
TCRX Yearly Current Assets VS Current LiabilitesTCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TCRX have decreased by -5.66% in the last year.
The Revenue for TCRX has decreased by -10.03% in the past year. This is quite bad
The Revenue for TCRX have been decreasing by -34.76% on average. This is quite bad
EPS 1Y (TTM)-5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
Revenue 1Y (TTM)-10.03%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%139.37%

3.2 Future

Based on estimates for the next years, TCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.04% on average per year.
Based on estimates for the next years, TCRX will show a very strong growth in Revenue. The Revenue will grow by 71.81% on average per year.
EPS Next Y4.68%
EPS Next 2Y7.99%
EPS Next 3Y8.12%
EPS Next 5Y8.04%
Revenue Next Year207.63%
Revenue Next 2Y71.74%
Revenue Next 3Y68.26%
Revenue Next 5Y71.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TCRX Yearly Revenue VS EstimatesTCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
TCRX Yearly EPS VS EstimatesTCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCRX. In the last year negative earnings were reported.
Also next year TCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRX Price Earnings VS Forward Price EarningsTCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRX Per share dataTCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.99%
EPS Next 3Y8.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TCRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TSCAN THERAPEUTICS INC

NASDAQ:TCRX (1/2/2026, 8:00:01 PM)

After market: 1.03 +0.01 (+0.98%)

1.02

+0.02 (+2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners73.34%
Inst Owner Change0%
Ins Owners0.26%
Ins Owner Change0%
Market Cap57.88M
Revenue(TTM)8.42M
Net Income(TTM)-142.60M
Analysts80
Price Target7.14 (600%)
Short Float %4.86%
Short Ratio3.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.6%
Min EPS beat(2)2.17%
Max EPS beat(2)7.04%
EPS beat(4)3
Avg EPS beat(4)3.16%
Min EPS beat(4)-7.46%
Max EPS beat(4)10.87%
EPS beat(8)6
Avg EPS beat(8)4.64%
EPS beat(12)8
Avg EPS beat(12)7.35%
EPS beat(16)12
Avg EPS beat(16)10.8%
Revenue beat(2)2
Avg Revenue beat(2)69.48%
Min Revenue beat(2)24.31%
Max Revenue beat(2)114.66%
Revenue beat(4)3
Avg Revenue beat(4)44.97%
Min Revenue beat(4)-51.71%
Max Revenue beat(4)114.66%
Revenue beat(8)4
Avg Revenue beat(8)15.52%
Revenue beat(12)5
Avg Revenue beat(12)10.41%
Revenue beat(16)7
Avg Revenue beat(16)9.29%
PT rev (1m)10.53%
PT rev (3m)-17.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.76%
EPS NY rev (1m)0%
EPS NY rev (3m)5.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.87
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-2.39
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS0.15
BVpS2.54
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.38%
ROE -99.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 179.54%
Cap/Sales 60.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.44
Quick Ratio 6.44
Altman-Z -3.39
F-Score2
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)78.03%
Cap/Depr(5y)175.46%
Cap/Sales(3y)60.67%
Cap/Sales(5y)133.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
EPS Next Y4.68%
EPS Next 2Y7.99%
EPS Next 3Y8.12%
EPS Next 5Y8.04%
Revenue 1Y (TTM)-10.03%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%139.37%
Revenue Next Year207.63%
Revenue Next 2Y71.74%
Revenue Next 3Y68.26%
Revenue Next 5Y71.81%
EBIT growth 1Y-24.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.23%
EBIT Next 3Y-3.95%
EBIT Next 5YN/A
FCF growth 1Y-135.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.9%
OCF growth 3YN/A
OCF growth 5YN/A

TSCAN THERAPEUTICS INC / TCRX FAQ

What is the ChartMill fundamental rating of TSCAN THERAPEUTICS INC (TCRX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCRX.


What is the valuation status of TSCAN THERAPEUTICS INC (TCRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to TSCAN THERAPEUTICS INC (TCRX). This can be considered as Overvalued.


How profitable is TSCAN THERAPEUTICS INC (TCRX) stock?

TSCAN THERAPEUTICS INC (TCRX) has a profitability rating of 1 / 10.


How financially healthy is TSCAN THERAPEUTICS INC?

The financial health rating of TSCAN THERAPEUTICS INC (TCRX) is 4 / 10.